Key opinion leader webinar: Context Therapeutics

Key opinion leader webinar: Context Therapeutics

Context Therapeutics — 4 videos in collection

More on this equity

Context Therapeutics (Nasdaq: CNTX) is a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers. The company’s robust clinical programme for lead candidate onapristone extended release (ONA-XR) comprises three Phase II clinical trials and one Phase Ib/II clinical trial in hormone-driven breast, ovarian and endometrial cancer. ONA-XR is a novel, first-in-class small molecule under development as a potent and specific antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. In this webinar, Context’s team and presenters from the American Association for Cancer Research (AACR) conference discuss the important company results presented at the AACR Annual Meeting 2022.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free